ATP1A1

Across TCGA pan-cancer cohorts, ATP1A1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of ATP1A1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ATP1A1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ATP1A1 is over-expressed in tumor, although a few such as CCRCC and COAD show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where ATP1A1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ATP1A1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.653	<.001	12	view →
LUAD	Female	III,IV	+0.557	<.001	8	view →
LSCC	Male	III,IV	+0.432	<.001	8	view →
PDAC	Male	IV	+1.050	.023	1	view →
COAD	Female	III,IV	−0.204	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

ATP1A1–CCRCC

Open the CCRCC breakdown →